Ki 67 is a major, but not the sole determinant of Oncotype Dx recurrence score

BACKGROUND: Immunohistological assessment of Ki 67 expression is less expensive than Oncotype Dx, which is currently used to identify patients with lymph node-negative breast cancer, who will benefit from adjuvant chemotherapy. METHODS: The relationship of immunohistologically measured Ki 67 to Onco...

Descripción completa

Detalles Bibliográficos
Autores principales: Sahebjam, S, Aloyz, R, Pilavdzic, D, Brisson, M-L, Ferrario, C, Bouganim, N, Cohen, V, Miller, W H, Panasci, L C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2011
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3241562/
https://www.ncbi.nlm.nih.gov/pubmed/21970880
http://dx.doi.org/10.1038/bjc.2011.402
_version_ 1782219530373693440
author Sahebjam, S
Aloyz, R
Pilavdzic, D
Brisson, M-L
Ferrario, C
Bouganim, N
Cohen, V
Miller, W H
Panasci, L C
author_facet Sahebjam, S
Aloyz, R
Pilavdzic, D
Brisson, M-L
Ferrario, C
Bouganim, N
Cohen, V
Miller, W H
Panasci, L C
author_sort Sahebjam, S
collection PubMed
description BACKGROUND: Immunohistological assessment of Ki 67 expression is less expensive than Oncotype Dx, which is currently used to identify patients with lymph node-negative breast cancer, who will benefit from adjuvant chemotherapy. METHODS: The relationship of immunohistologically measured Ki 67 to Oncotype DX recurrence score (RS) was examined in 53 cases of T1–2 N0 M0 (oestrogen receptor-positive, HER2/neu negative) breast cancer. RESULTS: There was a strong linear correlation between Ki 67 value and the Oncotype Dx RS. All patients in the low Ki 67 group (Ki 67 of ⩽10%) had Oncotype Dx RSs of low or intermediate risk. The vast majority of patients (93.8%) in the high-Ki 67 group (Ki 67⩾25%) had oncotype RSs of high or intermediate risk. CONCLUSION: Ki 67 proliferation value is a major, but not the sole determinant of Oncotype Dx score.
format Online
Article
Text
id pubmed-3241562
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-32415622012-10-25 Ki 67 is a major, but not the sole determinant of Oncotype Dx recurrence score Sahebjam, S Aloyz, R Pilavdzic, D Brisson, M-L Ferrario, C Bouganim, N Cohen, V Miller, W H Panasci, L C Br J Cancer Short Communication BACKGROUND: Immunohistological assessment of Ki 67 expression is less expensive than Oncotype Dx, which is currently used to identify patients with lymph node-negative breast cancer, who will benefit from adjuvant chemotherapy. METHODS: The relationship of immunohistologically measured Ki 67 to Oncotype DX recurrence score (RS) was examined in 53 cases of T1–2 N0 M0 (oestrogen receptor-positive, HER2/neu negative) breast cancer. RESULTS: There was a strong linear correlation between Ki 67 value and the Oncotype Dx RS. All patients in the low Ki 67 group (Ki 67 of ⩽10%) had Oncotype Dx RSs of low or intermediate risk. The vast majority of patients (93.8%) in the high-Ki 67 group (Ki 67⩾25%) had oncotype RSs of high or intermediate risk. CONCLUSION: Ki 67 proliferation value is a major, but not the sole determinant of Oncotype Dx score. Nature Publishing Group 2011-10-25 2011-10-04 /pmc/articles/PMC3241562/ /pubmed/21970880 http://dx.doi.org/10.1038/bjc.2011.402 Text en Copyright © 2011 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Short Communication
Sahebjam, S
Aloyz, R
Pilavdzic, D
Brisson, M-L
Ferrario, C
Bouganim, N
Cohen, V
Miller, W H
Panasci, L C
Ki 67 is a major, but not the sole determinant of Oncotype Dx recurrence score
title Ki 67 is a major, but not the sole determinant of Oncotype Dx recurrence score
title_full Ki 67 is a major, but not the sole determinant of Oncotype Dx recurrence score
title_fullStr Ki 67 is a major, but not the sole determinant of Oncotype Dx recurrence score
title_full_unstemmed Ki 67 is a major, but not the sole determinant of Oncotype Dx recurrence score
title_short Ki 67 is a major, but not the sole determinant of Oncotype Dx recurrence score
title_sort ki 67 is a major, but not the sole determinant of oncotype dx recurrence score
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3241562/
https://www.ncbi.nlm.nih.gov/pubmed/21970880
http://dx.doi.org/10.1038/bjc.2011.402
work_keys_str_mv AT sahebjams ki67isamajorbutnotthesoledeterminantofoncotypedxrecurrencescore
AT aloyzr ki67isamajorbutnotthesoledeterminantofoncotypedxrecurrencescore
AT pilavdzicd ki67isamajorbutnotthesoledeterminantofoncotypedxrecurrencescore
AT brissonml ki67isamajorbutnotthesoledeterminantofoncotypedxrecurrencescore
AT ferrarioc ki67isamajorbutnotthesoledeterminantofoncotypedxrecurrencescore
AT bouganimn ki67isamajorbutnotthesoledeterminantofoncotypedxrecurrencescore
AT cohenv ki67isamajorbutnotthesoledeterminantofoncotypedxrecurrencescore
AT millerwh ki67isamajorbutnotthesoledeterminantofoncotypedxrecurrencescore
AT panascilc ki67isamajorbutnotthesoledeterminantofoncotypedxrecurrencescore

Ejemplares similares